SEC Company Response from Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524) (JAZZ) — Dec 29, 2009
Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524)
Date: Dec. 29, 2009 · CIK: 0001232524 · Accession: 0001193125-09-261064
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-163333
Letter
Re: Jazz Pharmaceuticals, Inc.
Acceleration Request
December 29, 2009
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
Form S-1 Registration Statement (File No. 333-163333)
Ladies and Gentlemen:
Jazz Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective at 4:00 p.m. Eastern Time on December 30, 2009 or as soon thereafter as is practicable.
The Company hereby acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
JAZZ PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request December 29, 2009 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Jazz Pharmaceuticals, Inc. Form S-1 Registration Statement (File No. 333-163333) Ladies and Gentlemen: Jazz Pharmaceuticals, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective at 4:00 p.m. Eastern Time on December 30, 2009 or as soon thereafter as is practicable. The Company hereby acknowledges that: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Sincerely, JAZZ PHARMACEUTICALS, INC. By: /s/ Carol A. Gamble Carol A. Gamble Senior Vice President, General Counsel and Corporate Secretary cc: Bruce C. Cozadd, Chairman and Chief Executive Officer Philip J. Honerkamp, Vice President, Deputy General Counsel Chadwick L. Mills, Esq., Cooley Godward Kronish LLP